Bispecific antibodies have reshaped the therapeutic landscape for relapsed/refractory multiple myeloma (RRMM), complementing proteasome inhibitors, IMiDs, and anti-CD38 antibodies and competing with BCMA-directed CAR-T cells. In this review, we discuss the structure, mechanisms of action, and clinical data for currentl...
Mahin Bhatt, S. Rajkumar, Shaji K. Kumar· European Journal of Haematol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.